They are not late with the heart pre clinical. They stated 2Q.
Craig, I think originally they said the end of Q1 which sure, by the time they get everything analyzed and ready to go would be Q2, but how far into Q2?
I would have liked to hear something about the first pre-clinical testing in this recent PR. That's all I'm saying.
You have to remember a new patent was pulled in the course of the heart study. That has been the focus these last 4 months. There are a couple scenarios that might delay the results of the study. The most likely is that the entire study and findings will now be reviewed by a third party. That would add more credibility. A peer reveiwed study erases all doubt. Another scenerio could be that they are seeking FDA fast track approval and will announce it all at once. Ether way there is simply too much indication here to expect anything but positive results, in my opinion. This has been a very uncharacteristic quite period for Endonovo. In the fall they were pushing out a PR every week. I am expecting we will see that begin again and also a slue of articles and medical reviews. Remember they can not uplist without increasing pps dramatically from this point and they have stated that intent many times.
News 
Market Data 
Discover 
AI
